This report describes current global research initiatives in the field of allergies. It focuses on the most common allergies, which affect more than 300 million persons worldwide: seasonal and perennial allergic rhinitis and food allergies.
Sales estimates from 2008 to 2013 are provided for the leading prescription allergy drugs and vaccines, as well as over-the-counter (OTC) allergy medicines in the U.S., European Union, Japan and rest of world area (defined as South America and the Caribbean, Middle East, Africa, and Asia except Japan). Forecasts include an analysis of the market forces affecting sales in each region, as well as a discussion of patent expirations of leading medications and the effects of generic competition on existing allergy drug sales.
Allergy medications and vaccines under development are discussed, with a comprehensive analysis of technology, stage of development and commercialization potential. This includes new molecular entities and indication expansions of medicines currently approved for other uses. For leading allergy drug candidates, sales estimates from 2009 to 2013 are provided.
Profiles of the 12 leading allergy drug developers offer details of these companies’ capabilities, particularly focusing on R&D strength, pipeline products, strategic alliances and partnerships, and the effects of any recent merger or acquisition activity. A directory of more than five dozen leading players worldwide allows readers to access companies’ own web sites for further review.
Information for this report was gathered from a wide variety of published sources; interviews with company representatives were then conducted to assess trends, and form the basis of the forecasting and competitive analysis.
This report is designed for business development and other senior executives, marketers, R&D managers, investors, VCs, consultants, entrepreneurs and others who require an in-depth understanding of the current status of the allergy therapeutics market and potential new products. More than 50 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.
(0 items)
